News & Insights

20-NEU-1857239_acute-stroke-patient_650x450

Shorter Door-to-Needle Time Means Better Long-Term Outcomes in Acute Ischemic Stroke

One-year results from national database confirm enduring benefits

inside a mobile stroke unit

Mobile Stroke Units: The Latest Research and What to Expect Next

Q&A with Dr. Andrew Russman, Medical Director of our Comprehensive Stroke Center

20-NEU-1882828_SARS-CoV-2-microvillie_650x450
April 22, 2020/COVID-19

Neurologic Manifestations of COVID-19: What We Know Today

SARS-CoV-2’s potential for neuroinvasion and primary emerging neurologic features

Covid image 650×450
March 18, 2020/COVID-19

How to Counsel MS Patients on Disease-Modifying Therapy About COVID-19

In general, interrupting therapy is not advised, and patients should remain in contact with their provider teams

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

20-NEU-1832221-ISC-CQD-650×450-v3
February 25, 2020/Neurosciences/News & Insights

International Stroke Conference 2020: 5 Key Developments That Will Shape the Field

From B-PROUD to EXTEND-IA TNK to a novel TMS delivery method

19-NEU-6501-opioid-consortium-450×650
December 12, 2019/Neurosciences/News & Insights

Tackling Opioids as a Region: Q&A with Physician Chair of the Northeast Ohio Hospital Opioid Consortium

For this health crisis, a consortium is stronger than the sum of its parts

19-NEU-3973-vaccineMS-grant-650×450
September 19, 2019/Neurosciences/News & Insights

AAN Updates Its Guideline on Vaccines in Multiple Sclerosis: What Providers Need to Know

Recommendations revisited in wake of a surge in disease-modifying therapies

19-NEU-3860-alzheimer-brain-650×450
July 10, 2019/Geriatrics

Cleveland Alzheimer’s Disease Research Center to Be Created With $4.23 Million NIA Grant

Local population, deep expertise portend a center with high impact

19-NEU-461-opioid-consortium-450×650

Opioid Consortium Takes a Regional Approach to Turn the Tide in Addiction Epidemic

What we've contributed, gained and learned through the partnership

19-NEU-323_Parkinsons-Brain-650×450

SYN120 Fails to Show Efficacy Against Parkinson Dementia in Phase 2a SYNAPSE Trial

Disappointing performance for the dual serotonin receptor antagonist

BackPage 2 of 5Next

Advertisement

Ad